47 results about "Neutropenia" patented technology

The invention discloses a salt of ponabulin and application thereof, relates to the field of medicinal chemistry, and solves the problem that the curative effect is influenced by poor water solubility of ponabulin in the prior art. The invention provides a plurality of ponabulin salts, the salts are formed by ponabulin and inorganic acid or organic acid, and the structure of the ponabulin is shown as a formula I. The invention further provides a preparation method of the ponabulin salt. In addition, the invention finds that the solubility of p-toluenesulfonate and 1, 5-naphthalene disulfonate of ponabulin in water is remarkably improved by more than 2000 times compared with free alkali, so that the requirement that a solubilizer is not added or a few solubilizers are added in the injection preparation process can be met, and potential harm to human health in the long-term use process of the solubilizers can be prevented. Pharmacodynamic tests show that the salt of the ponabulin has good anti-tumor activity and an effect of relieving neutropenia, and is suitable for preparing anti-tumor drugs. # imgabs0 #

Provided herein are methods for reducing the likelihood and / or severity of peripheral neuropathy, anemia, and / or neutropenia in an individual being treated with an antibody-drug conjugate (ADC). Also provided herein are methods for increasing dosing amount and / or frequency of an antibody-drug conjugate (ADC) in an individual. In some embodiments, the methods comprise administering to the individual an effective amount of an ADC that comprises an antibody conjugated to a drug moiety via a linker, wherein the antibody comprises a heavy chain comprising a human Fc region with reduced or eliminated effector function. Compositions, uses, and kits related thereto are also provided.

This disclosure provides a method of preventing, alleviating, or treating a condition (i.e., neutropenia) in a patient in need thereof, the condition characterized by compromised white blood cell production in the patient. The method includes administering to the patient a therapeutically effective amount of a protein complex comprising a modified human granulocyte-colony stimulating factor (hG-CSF) covalently linked to an immunoglobulin Fc region via a non-peptidyl polymer. The non-peptidyl polymer is site-specifically linked to an N-terminus of the immunoglobulin Fc region, and the modified hG-CSF comprises substitutions in at least one of Cys17 and Pro65.

The invention features methods of treating a transfusion dependent subject having myelofibrosis, a cytopenia associated with myelofibrosis, such as anemia, thrombocytopenia, or neutropenia, or receiving treatment with a cytopenia-associated myelofibrosis treatment by administering to the subject an activin receptor type II (ActRII) signaling inhibitor, optionally in combination with a cytopenia- associated myelofibrosis treatment. The ActRII signaling inhibitor may be an antibody that binds to an ActRII ligand, an ActRII antibody, or an ActRII ligand trap.

The invention features methods of treating a disease or condition associated with elevated activin signaling (e.g., a bone disease, pulmonary hypertension, fibrosis, a muscle disease, a metabolic disease, thrombocytopenia, or neutropenia) by administering to a human subject a polypeptide including an extracellular ActRIIB variant fused to an Fc domain in an amount of 1.5 mg / kg to 4.5 mg / kg at a frequency of once every 28 days.

The invention discloses a traditional Chinese medicine prescription for treating myelosuppression after chemotherapy as well as a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine prescription is prepared from ten traditional Chinese medicines including caulis spatholobi, flos caryophylli, astragalus membranaceus, rhizoma cimicifugae, sanguisorba officinalis, hairyvein agrimony, rhodiola rosea, codonopsis pilosula, cinnamon and angelica sinensis, and has the effect of obviously improving myelosuppression after chemotherapy. Meanwhile, the traditional Chinese medicine composition has good curative effects on four types of myelosuppression after chemotherapy, including leucopenia, neutropenia, thrombocytopenia and over-low hemoglobin. The prescription is good in stability, high in safety and remarkable in curative effect.

Provided herein are bacterial compositions that are useful for treating and / or preventing a chronic liver disease, neutropenia, and / or a disease or disorder associated with a solid organ transplantation. In some aspects, treating and / or preventing comprises treating an infection complication due to a chronic liver disease, neutropenia, and / or a solid organ transplantation. The bacterial compositions disclosed herein are designed to exhibit one or more functional features that are useful for the treatment of such diseases and disorders.

The invention features polypeptides that include an extracellular ActRII chimera. In some embodiments, a polypeptide of the invention includes an extracellular ActRII chimera fused to an Fc domain or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness or atrophy of muscles, bone damage, low red blood cell levels (e.g., anemia or blood loss), low platelet levels (e.g., thrombocytopenia), low neutrophil levels (e.g., neutropenia), fibrosis, metabolic disorders, pulmonary hypertension, and / or diseases and conditions that can be treated with erythropoietin or an erythropoiesis-stimulating agent.

This application belongs to the field of microbial technology, and mainly relates to a strain of *Pediococcus lactis* BPA03 and its applications. *Pediococcus lactis* BPA03 is classified and named *Pediococcus lactis*. Pediococcus acidilactici This *Pediococcus lactis* strain BPA03 was deposited on September 28, 2025, at the China General Microbiological Culture Collection Center (CGMCC), located at No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing, with accession number CGMCC No. 36109. It inhibits skin melanin deposition and improves UV photoaging, suppresses the gene expression levels of immune factors such as IL-1β, IL-6, IL-8, and TNF-α, improves the activities of superoxide dismutase, catalase, and glutathione peroxidase, inhibits vinorelbine-induced neutropenia, and improves the inhibition of immune factor expression induced by vinorelbine, thus exhibiting comprehensive anti-aging effects.

The invention discloses a construction method and application of a neutropenia model. The model constructed by the method disclosed by the invention can be used for researching various related targets for neutropenia and other neutrophil differentiation and development disorder diseases, has in-vivo simulation and integrity, is obvious in phenotype, focuses on specific knockout of bone marrow myeloid cells, and has a good application prospect. The gene expression of other cell tissues is not influenced, the normal survival and reproduction state of animals is ensured while the significant phenotype is ensured, and the development of a long-period experiment is facilitated.

The invention features polypeptides that include an extracellular ActRII chimera. In some embodiments, a polypeptide of the invention includes an extracellular ActRII chimera fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, bone damage, low red blood cell levels (e.g., anemia or blood loss), low platelet levels (e.g., thrombocytopenia), low neutrophil levels (e.g., neutropenia), fibrosis, metabolic disorders, and / or pulmonary hypertension.

The invention features polypeptides that include an extracellular ActRIIB variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIB variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions containing said polypeptides and methods of using the polypeptides to treat diseases and conditions including neuromuscular diseases, osteogenesis imperfecta, myelofibrosis, thrombocytopenia, neutropenia, and metabolic disease.

Introduction: Rituximab (R) is an integral component of therapy for B-cell lymphoid malignancies; bortezomib (Btz) has shown provocative single agent activity in Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL) and Waldenstrom's Macroglobulinaemia (WM), providing the rationale for investigating the combination.Patients+Methods: Forty-five adult patients (pts.) (30 men, 15 women) with histologically confirmed recurrent CD20+ve FL, MCL or WM, median age 60 years (range 45-79), FL: 17, MCL: 18, WM: 10, stage III / IV 40 (93%), bone marrow (BM) infiltration 32 (73%), elevated LDH 22 (49%), performance status ≥1 22 (49%), were enrolled in a randomised trial comparing 2 schedules of Brz+R: Arm A (twice weekly) Btz: 1.3 mg / m2 (on days 1, 4, 8, 11 of a 21-day cycle) and R: 375 mg / m2 (on day 1) for 8 cycles, or Arm B (weekly) Btz: 1.6 mg / m2 (on days 1, 8, 15, 22 of a 35-day cycle) and R: 375 mg / m2 (on days 1, 8, 15, 22 of cycles 1 and 4) for 6 cycles (23 arm A, 22 arm B). The median number of previous treatments was 2 (range 1-7). Seventeen pts. had received a R-containing regimen, with response lasting >6 months, and 8 high-dose treatment. Response was evaluated using the IWR criteria (Cheson et al, JCO 17:1244, 1999) and the updated response criteria from the 3rd International Workshop on WM (Treon et al, Blood 107:3442, 2006)Results: Ability to deliver the therapy, toxicity and efficacy were equivalent in both arms. The median number of cycles given in arm A was 4 and 5 in arm B. Haematological toxicity (grade≥3: anaemia 0%, neutropenia 25%, thrombocytopenia 22%) was significantly influenced by the high percentage of pts. with BM infiltration and concomitant cytopenia on entry to the trial. The most common non-haematological adverse events were fatigue (76%), nausea (56%), diarrhoea (56%), lethargy (46%). Neurotoxicity occurred in 19 pts. (46%) (10 pts. grade 1, 7 pts. grade 2, 2 pts. grade 3). Btz dose was reduced in 7 pts.; 5 doses were omitted because of neuro or haematological toxicity. In 16 pts., treatment was delayed by 1-14 days and in 24 pts. treatment was stopped prematurely. The reasons for stopping treatment were: treatment-related toxicity 11 pts., progressive disease 9 pts., patient's preference 3 pts., myocardial infarction 1 pt. One pt. was excluded having been found ineligible post randomisation. Thirty-nine pts. (21 arm A, 18 arm B) are evaluable for response so far, one having only received 1 cycle of therapy, which had to be discontinued because of excessive toxicity. 15 / 32 were in remission (CR, CRu, PR) at the completion of therapy, 7 / 7 at “mid-therapy” assessment, and 5 have yet to be evaluated. Thus the overall response rate (RR) presently is 22 / 39 (56%) (CR, CRu, PR), FL 44%, MCL 46%, WM 90%.Conclusions:The combination was active in pts. with recurrent NHL especially WM (RR 90%), despite multiple previous treatments, The weekly schedule is preferable being more convenient, as efficacious and no more toxic.Further investigation is warranted, despite not insignificant therapy compromising toxicity.

The present invention provides a design of a trispecific antibody, a preparation method and use thereof. The trispecific antibody of the present invention comprises (a) anti-Her2 monoclonal antibody Herceptin, (b) anti-CD16a (FcgRIIIa) single-chain antibody scFv, (c) SIRPa D1 protein, and (d) a flexible linker; the heavy chain C-terminus of the antibody Herceptin is connected to the anti-CD16a single-chain antibody through a linker, and the light chain C-terminus of the antibody Herceptin is connected to SIRPa D1 through a linker; the Fc segment of the antibody is modified to change its binding ability with the receptor and prolong the half-life of the protein; tumor cells expressing CD47 can be targeted by binding to SIRPa D1 and CD47 ligand; at the same time, a "don't eat me" signal can be blocked to activate macrophages to phagocytize tumor cells; anti-CD16a specifically binds to NK (Nature Killing) cells; therefore, macrophages and NK cells in the tumor microenvironment are recruited through SIRPa and anti-CD16a to kill tumor cells; the present invention ensures the specificity of anti-CD16a and does not cause side effects (neutropenia) caused by binding to CD16b on the surface of neutrophils.

This disclosure provides a method of preventing, alleviating or treating a condition (i.e., neutropenia) in a subject in need thereof, the condition characterized by compromised white blood cell production in the subject. The method includes administering to the subject a therapeutically effective amount of a protein complex on the same day as a chemotherapy regimen, wherein the protein complex is a modified human granulocyte-colony stimulating factor (hG-CSF) covalently linked to an immunoglobulin Fc region via a non-peptidyl polymer. The non-peptidyl polymer is site-specifically linked to an N-terminus of the immunoglobulin Fc region, and the modified hG-CSF comprises substitutions in at least one of Cys17 and Pro65.

The invention features polypeptides that include an extracellular ActRII chimera. In some embodiments, a polypeptide of the invention includes an extracellular ActRII chimera fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, bone damage, low red blood cell levels (e.g., anemia or blood loss), low platelet levels (e.g., thrombocytopenia), low neutrophil levels (e.g., neutropenia), fibrosis, metabolic disorders, and / or pulmonary hypertension.

Methods and compositions containing a phorbol ester or a derivative of a phorbol ester in combination with G-CSF or in combination with EPO, are provided for the treatment of cytopenia in mammalian subjects. The compositions and methods also reduce the duration of cytopenia such as neutropenia, thrombocytopenia, and / or anemia.

Provided are methods for the treatment of SCLC patients by administering therapeutic amounts of lurbinectedin by intravenous infusion. Also provided are methods of treating cancer by administering lurbinectedin in combination with other anticancer drugs, in particular topoisomerase inhibitors. The invention further relates to the administration of lurbinectedin in combination with anti-emetic agents for effective control of symptoms related to nausea and vomiting, reduced lurbinectedin dosages to achieve a safer administration and an increase in the number of treatment cycles. Stable lyophilized formulations of lurbinectedin are also provided.

The present invention relates to a promoting of hematological recovery when using chemotherapy. It has been observed that a Clever-1 inhibitor can be used for the treatment of cancer together with chemotherapy to prevent and treat chemotherapy-induced suppression of the bone marrow and / or chemotherapy-induced lymphopenia and neutropenia.

The embodiments disclosed herein may provide digital medical support to predict and mitigate side effects of bispecific antibody therapy (e.g., Pfizer's erlanatamab) for myeloma patients. Side effects may include cytokine release syndrome (CRS), infections (e.g., sepsis), neurotoxicity (e.g., peripheral neuropathy), cytopenias (e.g., neutropenia), and the like. These side effects may be predicted based on passive collection of data from patient wearables, patient-entered data on healthcare applications, and other data such as blood test data. Trained machine learning models may be used to predict side effects. Because side effects may be predicted prior to their onset, preventative interventions may be feasible to improve healthcare outcomes for myeloma patients.

The invention provides an irinotecan hydrochloride lipidosome composition. The irinotecan hydrochloride lipidosome composition is prepared from the following components in a specific weight ratio: irinotecan hydrochloride, hydrogenated soybean phospholipid, cholesterol and mPEG2000-DSPE. The invention also provides a preparation method of the liposome composition. The liposome disclosed by the invention can be used for remarkably reducing the serious hematotoxicity of irinotecan hydrochloride, and particularly remarkably reducing the occurrence rate of neutropenia.

This invention discloses a predictive model for early fever and infection after CAR-T therapy. The equation for this predictive model is: P = 1 / (1 + e^(-3.23 + 0.017 × CRP + 0.003 × IL - 6 - 0.023 × platelet count - 8.048 × lymphocyte count - 1.241 × FCV + 1.6146 × neutropenia grade)); where P is the probability of infection. P < 0.20 is defined as low risk, classified as CRS; 0.2 ≤ P ≤ 0.6 is defined as medium risk, requiring further testing to determine whether it is infection or CRS; P > 0.6 is defined as high risk, classified as infection. This predictive model is used to predict the likelihood of infection in the first fever event after CAR-T therapy. By analyzing various clinical laboratory indicators and combining logistic regression analysis, the model screens out key predictive factors related to infection risk, ultimately establishing an efficient and easy-to-use predictive tool. This model can effectively predict the occurrence of infection, provide clinicians with guidance for early intervention, reduce unnecessary clinical testing, and optimize patients' treatment plans.

The present invention relates to a pharmaceutical composition comprising a protein complex, and its pharmaceutical applications for treating or preventing conditions characterized by impaired leukocyte production, such as neutropenia. The protein complex can also be formed by linking an immunoglobulin Fc region to a bioactive polypeptide via a non-peptide polymer linked to the immunoglobulin Fc region. [Solution] The present invention provides a method for treating chemotherapy-induced neutropenia in patients who require it by administering an effective amount of efrapegrastim to the patient, and a method for treating radiation-induced neutropenia in patients who require it by administering an effective amount of efrapegrastim to the patient.

The application provides a use of vincristine and lithium carbonate as co-active ingredients in the preparation of a medicament for treating tumors. The vincristine and lithium carbonate as co-active ingredients of the application have a killing effect on various leukemia cells, including human acute lymphoblastic leukemia cell lines, chronic myeloid leukemia cells, acute monocytic leukemia cell lines; in particular, for human acute lymphoblastic leukemia cell lines, compared with single free drugs (lithium carbonate or vincristine), lithium carbonate and vincristine free drug combination, the leukemia cell proliferation can be more effectively inhibited; in addition, the vincristine and lithium carbonate as co-active ingredients of the application can obviously stimulate the generation of granulocyte colony-stimulating factor, and alleviate the neutropenia side effect caused by chemotherapy.

This invention discloses a traditional Chinese medicine composition for treating neutropenia and / or T-cell cytopenia, its preparation method, and its application. The composition mainly consists of Astragalus membranaceus, Angelica sinensis, ginseng / Codonopsis pilosula, Ganoderma lucidum, Lycium barbarum, and Glycyrrhiza uralensis in a specific ratio. It has a dual effect of increasing neutrophil count and promoting thymic development and T-cell function (enhancing T-cell function). Through multiple pathways, including stimulating hematopoietic progenitor cell proliferation and differentiation, improving the thymic microenvironment, and activating innate and adaptive immunity, it effectively improves the state of reduced immune cells and enhances the body's anti-infection ability.

The invention discloses an application of a flavonoid compound 5-demethylated sweet orange flavone in preparation of a medicine for treating hemogenic acute radiation syndrome, and relates to the technical field of biological medicines. The medicine 5-demethylated sweet orange flavone (DMSS) is obtained through high-throughput screening of a zebra fish irradiation granulocyte reduction (granulocyte reduction) model, and the new application of the medicine for effective radiation resistance is verified in cell and mouse irradiation models. The invention discloses the protective effect of DMSS in irradiation-induced hematopoietic injury for the first time, irradiation protection is realized by relieving irradiation-induced neutrophil apoptosis, and as a novel protective agent, the anti-oxidation, anti-inflammatory, anti-tumor and other activities of DMSS are proved in various disease models. Therefore, compared with a synthetic radiation protective agent, DMSS has lower toxic and side effects and better clinical transformation potential, and the unique action mechanism of DMSS provides a new candidate molecule for drug treatment of acute radiation injury of a hematopoietic system.

The invention features polypeptides that include an extracellular ActRIIB variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIB variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions containing said polypeptides and methods of using the polypeptides to treat diseases and conditions including neuromuscular diseases, osteogenesis imperfecta, myelofibrosis, thrombocytopenia, neutropenia, and metabolic disease.

This disclosure provides a method of preventing, alleviating, or treating a condition (i.e., neutropenia) in a patient in need thereof, the condition characterized by compromised white blood cell production in the patient. The method includes administering to the patient a therapeutically effective amount of a protein complex comprising a modified human granulocyte-colony stimulating factor (hG-CSF) covalently linked to an immunoglobulin Fc region via a non-peptidyl polymer. The non-peptidyl polymer is site-specifically linked to an N-terminus of the immunoglobulin Fc region, and the modified hG-CSF comprises substitutions in at least one of Cys17 and Pro65.

The invention relates to a new agent for the prophylaxis and / or treatment of neutropenia, a pharmaceutical composition comprising said agent, and to a method for the prophylactic and / or therapeutic treatment of neutropenia.

The invention features methods of treating a transfusion dependent subject having myelofibrosis, a cytopenia associated with myelofibrosis, such as anemia, thrombocytopenia, or neutropenia, or receiving treatment with a cytopenia-associated myelofibrosis treatment by administering to the subject an activin receptor type II (ActRII) signaling inhibitor, optionally in combination with a cytopenia- associated myelofibrosis treatment. The ActRII signaling inhibitor may be an antibody that binds to an ActRII ligand, an ActRII antibody, or an ActRII ligand trap.